Conpharm 2018 Learning Objectives and Competencies

Friday 15 June 2018

Pain Management Masterclass – Dr Geoffrey Harding 9.00am to 12.00 noon

After completing this activity, pharmacists should be able to

  • Describe the assessment and management of chronic non-cancer pain
  • Recognise the complexity of chronic pain and the benefits of a multidimensional approach to its assessment and management
  • Recognise and explain the limitations of codeine in managing chronic pain
  • Support best practice principles when opioid analgesics are used in the management of moderate to severe chronic non-cancer pain

2010 Competencies: 1.3, 2.3, 4.2, 6.1, 6.2, 6.3, 7.1, 7.2
2016 Competencies: 2.1, 2.2, 3.1, 3.2, 3.3, 3.5, 3.6

Accreditation Number: A1806AACP1A    EXP: 1/6/2019
This activity has been accredited for 3.0 hours of Group One CPD (or 3.0 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 3.0 hours of Group Two CPD (or 6.0 CPD credits) upon successful completion of relevant assessment activities.

Case Study workshop – Dr Andrew Stafford 9.00am to 11.30am

By the end of this workshop, pharmacists should be able to:

  • Utilise individual patient characteristics and priorities to identify medication-related issues
  • Synthesise patient-centric medication management plans

2010 Competency Standards: 1.3, 2.3, 4.2, 6.2, 7.1, 7.2, 7.3
2016 Competency Standards: 1.5, 2.2, 3.1, 3.3, 3.5

Accreditation Number: A1806AACP1B    EXP: 1/6/2019
This activity has been accredited for 2.5 hours of Group One CPD (or 2.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 2.5 hours of Group Two CPD (or 5.0 CPD credits) upon successful completion of relevant assessment activities.

Cancer as chronic disease – improving the quality of life for patients with cancer – the role of the accredited pharmacist – Professor David Currow 12.45pm to 1.30pm

After completing this activity pharmacists should be able to:

  • Describe the expected changes in cancer incidence and rates of cancer
  • Identify the proportion of people for whom cancer is currently a chronic disease
  • Explain the effect of smoking cessation at the time of diagnosis of cancer on mortality
  • Discuss a key role for pharmacists as new therapies develop for cancer treatment

2010 Competencies: 1.3, 4.3, 6.2, 6.3
2016 Competencies: 3.1, 3.2, 3.6

Accreditation Number: A1806AACP2    EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Advanced management of Parkinson’s disease – beyond the ‘shaking palsy’ – Professor Peter Silburn 1.30pm to 2.15pm

After completing this activity pharmacists should be able to:

  • Describe the economic impact of Parkinson’s Disease in Australia
  • List the motor features of Parkinson’s Disease
  • Identify the neurotransmitters which are involved the most in Parkinson’s Disease

2010 Competencies: 1.3, 4.2, 6.2, 7.1, 7.2
2016 Competencies: 3.1, 3.2, 3.5

Accreditation Number: A1806AACP4    EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Osteoarthritis – Wearing Australia Down – Dr Paul Kubler 2.15pm to 3.00pm

After completing this activity pharmacists should be able to:

  • Describe the clinical features of osteoarthritis, including the limited role of imaging tests in assessing the condition
  • List the factors associated with pain and structural deterioration in osteoarthritis Formulate individual treatment plans for patients with osteoarthritis etc.
  • Describe the relative magnitude of treatment related benefits

2010 Competencies: 1.3, 6.1, 6.2, 6.3, 7.2
2016 Competencies: 2.1, 3.1, 3.2, 3.6

Accreditation Number: A1806AACP3    EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

SGLT2 inhibitors – real world experience – Dr Gary Deed 3.30pm to 4.15pm

After completing this activity pharmacists should be able to:

  • Explain the physiology of SGLT2 inhibitors which make them a novel class of oral agents for use in type 2 diabetes
  • Critically examine clinical trial differences in patient selection and compare/contrast these to patients in Australian practice, specific to efficacy and safety of the SGLT2i’s
  • Describe the major cardiovascular safety trials that have led to TGA changes in the indication of some of these agents

2010 Competencies: 4.2, 7.2, 7.3
2016 Competencies:  3.2, 3.5

Accreditation Number: A1806AACP5    EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Insulin use in those with type 2 diabetes –strategies to reduce the barriers – Anne Marie Parisi 4.15pm to 4.45pm

After completing this activity pharmacists should be able to:

  • Describe the patient barriers to commencement of insulin
  • Describe physician barriers to initiation of insulin
  • Discuss the various strategies that may assist patients in making therapy change
  • Explain how accredited pharmacists may be involved in supporting patients and GPs with insulin initiation/intensification regimens

2010 Competencies: 1.3, 2.1, 4.2, 7.1, 7.2
2016 Competencies: 2.1, 2.3, 3.1, 3.2, 3.5

Accreditation Number: A1806AACP6    EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hour of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Reducing antibiotic prescribing in Australian general practice: time for a national strategy – Professor Mieke van Driel 4.45pm to 5.30pm

After completing this activity pharmacists should be able to:

  • Describe the drivers for antimicrobial resistance and strategies to reduce its impact
  • Describe antibiotic use in Australia
  • Describe interventions aimed at reducing antibiotic prescribing in the community and the evidence supporting their effectiveness
  • Describe the evidence for gaps in patient/consumer knowledge about antibiotics and the roles clinicians and pharmacists can play

2010 Competencies: 1.3, 4.2, 7.1, 7.2, 7.3
2016 Competencies:  2.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP7    EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.   

Saturday 16 June 2018

Osteosarcopenia: Use it or lose it – Dr Anthony French 9.00am to 9.45am

After completing this activity pharmacists should be able to:

  • Describe the prevalence and mechanisms of this new geriatric syndrome
  • Outline the diagnostic strategies and the importance of identification of osteosarcopenia
  • Discuss preventative strategies and treatment approaches to reduce the impact of this syndrome
  • Describe the complex changes in ageing that lead to this syndrome
  • Explain the potential impact of this syndrome on future health resources

2010 Competencies: 1.3, 6.1, 6.2, 6.3
2016 Competencies: 2.1, 3.1, 3.2, 3.6

Accreditation Number: A1806AACP8      EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Managing patient expectations when ‘alternative’ medicines are requested for chronic disease management – Adjunct Associate Professor Geraldine Moses 9.45am to 10.30am

After completing this activity pharmacists should be able to:

  • Discuss the motives that drive complementary medicine use.
  • Describe the skills and knowledge required to assist consumers to have realistic expectations of what complementary meds can achieve
  • Plan the use of complementary medicines to maximise benefits and minimise risks

2010 Competencies: 1.3, 7.1, 7.2
2016 Competencies: 2.1, 3.1, 3.3, 3.5

Accreditation Number: A1806AACP9      EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Health 5.0 – Pharmacists in the age of digital wellness – Professor Lisa Nissen 10.30am to 11.00am

After completing this activity pharmacists should be able to:

  • List the key factors influencing the future the health system
  • Describe emerging digital health technologies
  • Discuss the role pharmacists can contribute in improving patient outcomes in this complex future environment

2010 Competencies: 1.3, 2.1, 6.3
2016 Competencies: 2.1, 2.3, 3.6

Accreditation Number: A1806AACP10      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Persistent pain and opioid use – Dr Heide Feberwee 11.30am to 12.00 noon

After completing this activity pharmacists should be able to:

  • Describe the prevalence of chronic pain
  • List medication combinations increasing the risk of community death
  • Describe the role of the pharmacist in opioid management

2010 Competencies: 1.3, 4.1, 4.2, 7.1, 7.2
2016 Competencies: 2.1, 3.1, 3.2, 3.5

Accreditation Number: A1806AACP11      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Self-management of Pain in Older Adults – Joyce McSwan 12.00 noon to 12.30pm

After completing this activity, pharmacists should be able to:

  • Describe the impact of chronic pain in the older person
  • Identify the barriers and facilitators of self-management and assisting the patient to improve their health literacy in their own self-management
  • Discuss the various active and passive treatment techniques that can assist to motivate towards
  • achieving a self-management plan for older persons suffering chronic pain.

2010 Competencies: 1.3, 2.3, 6.1, 6.2, 6.3
2016 Competencies: 2.1, 3.1, 3.2, 3.6

Accreditation Number: A1806AACP12      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Is it nerve pain? Management and treatment approaches for neuropathic pain – Dr Matthew Keys 12.30pm to 1.00pm

After completing this activity, pharmacists should be able to:

  • List the various types of neuropathic pain
  • Describe the various mechanisms associated with causing neuropathic pain
  • Identify symptoms of neuropathic pain and when to refer to doctor
  • Explain the difference between neuropathic pain and localised neuropathic pain and the respective treatment options

2010 Competencies: 1.3, 2.3, 4.2, 7.1, 7.2
2016 Competencies: 2.1, 3.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP13      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Recent advances in Heart Failure management – Cassandra Vale 2.00pm to 2.30pm

After completing this activity, pharmacists should be able to:

  • Explain the importance of community-based services and allied health in the management of heart failure
  • Identify classifications of heart failure and changes in their respective management
  • Describe the role of angiotensin receptor/neprilysin inhibitors in heart failure management

2010 Competencies: 1.3, 4.2, 7.1, 7.2
2016 Competencies: 2.1, 3.1, 3.2, 3.5

Accreditation Number: A1806AACP14      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Dual antiplatelet therapy: how, how long, and in which patients? – Dr Naranjin Gaikwad 2.30pm to 3.15pm

After completing this activity pharmacists should be able to:

  • Explain the need for Dual Antiplatelet Therapy for patients post ACS and the implications of the underlying disease on patient outcomes
  • Discuss the treatment options and their differing drug characteristics when it comes to Oral Antiplatelet medications
  • Outline guideline recommendations for Dual Antiplatelet medication for ACS patients and know how to access these resources
  • List the key reasons why ACS patients discontinue their Dual Antiplatelet medication
  • Explain the need for triple therapy and the guideline recommendations that apply to this patient group

2010 Competencies: 1.3, 4.2, 7.1, 7.2
2016 Competencies: 3.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP15      EXP: 1/6/2019
This activity has been accredited for 0.75 hours of Group One CPD (or 0.75 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.75 hours of Group Two CPD (or 1.5 CPD credits) upon successful completion of relevant assessment activities.

Clinical use of the My Health Record – Dr Shane Jackson 3.45pm to 4.15pm

After completing this activity, pharmacists should be able to:

  • List the features and benefits of the My Health Record system in pharmacy practice
  • Describe how more comprehensive health information (accessed via My Health Records) can contribute to patient care
  • Describe how pharmacists can utilise the My Health Record system to improve patient care

2010 Competencies: 1.2, 1.3, 1.4, 2.3, 6.1, 6.2
2016 Competencies: 1.1, 1.4, 2.2, 3.1, 3.2, 3.3

Accreditation Number: A1806AACP16      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

GORD – Classification, complications and clinical considerations – Dr Brett MacFarlane 4.15pm to 4.45pm

After completing this activity pharmacists should be able to:

  • Describe the condition GORD
  • Outline the potential complications of GORD
  • Discuss an overview of clinical GORD management

2010 Competencies: 1.3, 4.2, 6.1, 6.2, 7.1
2016 Competencies:  3.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP17      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

QUM principles and PPI use in GORD – Zain Elgebaly 4.45pm to 5.15pm

After completing this activity pharmacists should be able to:

  • Discuss management expectations including treatment duration and lifestyle modifications with patients starting PPIs for GORD
  • Support patients who may benefit from stepping down their PPI treatment.
  • Discuss strategies to manage potential symptoms of rebound acid hypersecretion when stopping a PPI
  • List measures that may assist in mitigating potential risks associated with PPI use

2010 Competencies: 1.3, 4.2, 6.2, 7.1
2016 Competencies:  3.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP18      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Sunday 17 June 2018

Heading off dementia: Interventions to prevent or slow cognitive decline – Dr Andrew Stafford 9.00am to 9.30am

After completing this activity, pharmacists should be able to:

  • Describe the major risk factors for the development of dementia
  • Assess the potential cognitive benefits and detrimental effects of:
    • Proton pump inhibitors
    • Antidepressants

2010 Competencies: 1.3, 4.2, 6.3, 7.1, 7.2
2016 Competencies: 2.1, 3.2, 3.5, 3.6

Accreditation Number: A1806AACP19      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

The comprehensive behaviour assessment – use of evidence based non-pharmacological management strategies to manage behaviours associated with dementia – Professor Elizabeth Beattie 9.30am to 10.00am

After completing this activity pharmacists should be able to:

  • Identify several explanatory models of behavior changes associated with dementia and the current evidence base for the use of non-pharmacological interventions to improve comfort and quality of life.
  • Recognise the complex, inter-related factors involved in the assessment of ‘responsive behaviours’ and the development, enactment, adjustment and evaluation of care strategies.
  • Appreciate the critical role of the pharmacist in the team effort to improve the comfort of the person experiencing ‘responsive‘ behaviours.

2010 Competencies: 1.3, 2.3, 6.1, 6.2, 6.3
2016 Competencies: 2.2, 3.1, 3.2, 3.6

Accreditation Number: A1806AACP20      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Medicinal Cannabis – Dr Sue Ballantyne 10.00am to 10.30am

After completing this activity, pharmacists should be able to:

  • Identify the main cannabinoids used in medicinal cannabis products
  • Explain the differences between street and medicinal cannabis
  • Discuss the types of cannabis medicines available in Australia
  • Describe the evidence-base for the prescribing of cannabis medicines for specific health conditions.

2010 Competencies: 1.1, 1.3, 4.2, 7.1, 7.2
2016 Competencies: 1.3, 3.1, 3.2, 3.5

Accreditation Number: A1806AACP21      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

An exploration and evaluation of the work processes of accredited pharmacists performing HMRs – Marea Patounas 11.00am to 11.30am

After completing this activity pharmacists should be able to:

  • Describe a recent systematic review of clinical medication reviews in Australia
  • Explain issues and problems reported by patients about pharmacists performing Home Medicines Reviews in Australia
  • Describe a human factors’ framework for studying and improving the work of healthcare professionals and patients – SEIPS 2.0 Model

2010 Competencies: 1.3, 2.1, 2.3
2016 Competencies:  2.1, 2.2, 2.3

Accreditation Number: A1806AACP22      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Integrating clinical pharmacists into residential aged care homes to improve quality use of medicines – Nicole McDerby, Richard Thorpe & Tamra MacLeod 11.30am to 12.00 noon

After completing this activity pharmacists should be able to:

  • Discuss preliminary findings around key outcomes
  • Discuss the practical aspects of employment as a residential care pharmacist
  • Discuss the residential care pharmacist role from the perspective of nursing and care staff

2010 Competencies: 1.3, 2.3, 7.1, 7.2, 7.3
2016 Competencies:  2.1, 2.2, 3.2, 3.5

Accreditation Number: A1806AACP23      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

Deprescribing in community living older people – Can and should it be done? – Kristen Anderson 12.00 noon to 12.30pm

After completing this activity pharmacists should be able to:

  • Outline key findings of the exploratory study by Anderson et al in which a pragmatic, GP-led deprescribing intervention was piloted
  • Describe from qualitative research with GPs and consultant pharmacists why deprescribing in this patient group can be challenging
  • Apply these learnings to identify opportunities to better support patients and their GPs when attempting to deprescribe potentially inappropriate medicines in routine practice

2010 Competencies:  1.3, 2.3, 7.1, 7.2
2016 Competencies: 2.2, 3.1, 3.3, 3.5

Accreditation Number: A1806AACP24      EXP: 1/6/2019
This activity has been accredited for 0.5 hours of Group One CPD (or 0.5 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.5 hours of Group Two CPD (or 1.0 CPD credits) upon successful completion of relevant assessment activities.

The ACCHO Pharmacist – An emerging area of practice for accredited pharmacists – Chris Braithwaite 12.30pm to 12.45pm

After completing this activity, pharmacists should be able to:

  • Describe what an ACCHO is, how pharmacists can contribute, and how they deliver healthcare to Aboriginal and Torres Strait Islander people
  • Discuss the role of an ACCHO pharmacist and clinical issues relating to Aboriginal and Torres Strait Islander health

2010 Competencies: 1.3, 2.3, 7.1, 7.2
2016 Competencies: 2.1, 2.2, 3.1, 3.2

Accreditation Number: A1806AACP25      EXP: 1/6/2019
This activity has been accredited for 0.25 hours of Group One CPD (or 0.25 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 0.25 hours of Group Two CPD (or 0.5 CPD credits) upon successful completion of relevant assessment activities.

Clinical controversies and Practice Pointers – various presenters 1.45pm to 3.45pm
PC5K9 inhibitors: when statins aren’t enough – Dr Andrew Stafford

After completing this activity, pharmacists should be able to:

  • Describe the mechanism of action of PCSK9 inhibitors
  • Explain the clinical outcomes associated with PCSK9 inhibitors
  • Evaluate the appropriateness of PCSK9 inhibitors for cardiovascular risk reduction based on individual patient factors

2010 Competencies: 7.1, 7.2
2016 Competencies: 3.5

Why pharmacists should challenge claims of penicillin allergy – Dr Geraldine Moses

After completing this activity pharmacists should be able to:

  • Describe the negative impact of over-reporting of penicillin allergy
  • Discuss how to challenge penicillin allergy claims and give appropriate advice on cross reactivity w/ cephalosporins
  • Document allergies accurately and in detail

2010 Competencies: 1.3, 4.2, 6.1, 7.1, 7.2
2016 Competencies:  3.1, 3.2, 3.3, 3.5

Overview of the gut brain axis and probiotics in mental health – Dr Brett MacFarlane

After completing this activity pharmacists should be able to:

  • Describe the interaction between the central nervous system and the gut (the Gut-Brain Axis)
  • Outline the emerging evidence supporting the role of probiotics in mental health

2010 Competencies: 4.2, 6.2, 7.1, 7.2
2016 Competencies:  3.1, 3.2, 3.5

Gabapentinoids – friends or foes? – Tony Hall

After completing this activity pharmacists should be able to:

  • Recognise the appropriate place for Gabapentinoid AEDs in persistent pain pharmacotherapeutics
  • Explain current theories on the mechanism of action of gabapentinoids analgesic adjuncts
  • Recognise the common adverse reaction profile for gabapentinoids analgesics and the differences between gabapentin and pregabalin
  • Discuss how gabapentinoids adjuncts are being misused or abused

2010 Competencies: 1.3, 4.2, 7.1, 7.2, 7.3
2016 Competencies: 2.1, 3.2, 3.3, 3.5

Accreditation Number: A1806AACP26      EXP: 1/6/2019
Note that Accreditation number is for the overall 2-hour activity
This activity has been accredited for 2.0 hours of Group One CPD (or 2.0 CPD credits) suitable for inclusion in an individual pharmacist’s CPD plan which can be converted to 2.0 hours of Group Two CPD (or 4.0 CPD credits) upon successful completion of relevant assessment activities.